Research programme: insulin analogues biosimilars - Stelis Biopharma

Drug Profile

Research programme: insulin analogues biosimilars - Stelis Biopharma

Alternative Names: SBL 012

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stelis Biopharma
  • Class Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 09 Mar 2018 Research programme: insulin analogues biosimilars - Stelis Biopharma is available for licensing as of 09 Mar 2018. (Stelis Biopharma website, March 2018)
  • 09 Mar 2018 Stelis Biopharma expects to launch SBL 012 globally, in 2019 (Stelis Biopharma pipeline, March 2018)
  • 07 Mar 2018 Preclinical trials in Diabetes mellitus in India (Parenteral) (Stelis Biopharma pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top